Cardiopulmonary exercise testing before and after intravenous iron in preoperative patients: a prospective clinical study.

"Declarations Ethics approval and consent to participateEthical approval was granted by the London—Surrey Research Ethics Committee and NHS Health Research Authority (REC reference 17/LO/2061). Local permissions were received from the University of Southampton (ERGO ID: 31688), University Hospital Southampton NHS Foundation Trust (R&D CRI 0357) and Southampton Centre for Biomedical Research Clinical Research Facility. The study was performed in accordance with the ethical standard set by the Declaration of Helsinki. Written informed consent was obtained from all participants. Consent for publicationAs above all patients were formally consented. Competing interestsJOMP: Received financial support from Siemens Healthcare Ltd for consumables and hardware for research into the measurement of haemoglobin mass (2015–2018). JOMP was given consumables from Intersurgical UK Ltd (2015–2018); has received honoraria for speaking and/or travel expenses from Siemens, Vifor Pharma and Pharmacosmos Ltd. JOMP has received unrestricted grant funding from Pharmacosmos Ltd. JOMP is unaware of any direct or indirect conflict of interest with the contents of this paper or its related fields. The design of this study was researcher led with no input from Pharmacosmos Ltd.JMO: No conflicts of interest.SK: No conflicts of interest.SB: No conflicts of interest.MW: Received honoraria for speaking and/or travel expenses from Pharmacosmos Ltd.WS: Managing partner of the company ‘Blood tec GmbH’, but he is unaware of any direct or indirect conflict of interest with the contents of this paper.HEM: On the Council of the UK Intensive Care Society but is unaware of any direct or indirect conflict of interest with the contents of this paper or its related fields.MPWG: Vice-president of CPX International. He also serves on the medical advisor board of Edwards Lifesciences and the board of EBPOM Community Interest Company, Medinspire Ltd and Oxygen Control Systems Ltd. He has received honoraria for speaking for and/or travel expenses from BOC Medical (Linde Group), Edwards Lifesciences and Cortex GmBH and unrestricted research support from Sphere Medical Ltd and Pharmacosmos Ltd. He leads the Fit-4-Surgery research collaboration and the Xtreme Everest oxygen research consortium, which has received unrestricted research grant funding from BOC Medical (Linde Group), Deltex Medical and Smiths Medical. He was funded in part from the British Oxygen Company Chair of the Royal College of Anaesthetists awarded by the National Institute of Academic Anaesthesia. All funding was unrestricted. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript. This work was conducted at the Southampton NIHR Biomedical Research Centre with subjects studied within the Southampton NIHR Clinical Research Facility.DZL: On the board of CPX International a society supporting cardiopulmonary exercise testing and a member of the fit-4-surgery research group in Southampton. DL has received unrestricted research support from Pharmacosmos Ltd. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript. This work was conducted at the Southampton NIHR Biomedical Research Centre with subjects studied within the Southampton NIHR Clinical Research Facility. Competing interests JOMP: Received financial support from Siemens Healthcare Ltd for consumables and hardware for research into the measurement of haemoglobin mass (2015–2018). JOMP was given consumables from Intersurgical UK Ltd (2015–2018); has received honoraria for speaking and/or travel expenses from Siemens, Vifor Pharma and Pharmacosmos Ltd. JOMP has received unrestricted grant funding from Pharmacosmos Ltd. JOMP is unaware of any direct or indirect conflict of interest with the contents of this paper or its related fields. The design of this study was researcher led with no input from Pharmacosmos Ltd. JMO: No conflicts of interest. SK: No conflicts of interest. SB: No conflicts of interest. MW: Received honoraria for speaking and/or travel expenses from Pharmacosmos Ltd. WS: Managing partner of the company ‘Blood tec GmbH’, but he is unaware of any direct or indirect conflict of interest with the contents of this paper. HEM: On the Council of the UK Intensive Care Society but is unaware of any direct or indirect conflict of interest with the contents of this paper or its related fields. MPWG: Vice-president of CPX International. He also serves on the medical advisor board of Edwards Lifesciences and the board of EBPOM Community Interest Company, Medinspire Ltd and Oxygen Control Systems Ltd. He has received honoraria for speaking for and/or travel expenses from BOC Medical (Linde Group), Edwards Lifesciences and Cortex GmBH and unrestricted research support from Sphere Medical Ltd and Pharmacosmos Ltd. He leads the Fit-4-Surgery research collaboration and the Xtreme Everest oxygen research consortium, which has received unrestricted research grant funding from BOC Medical (Linde Group), Deltex Medical and Smiths Medical. He was funded in part from the British Oxygen Company Chair of the Royal College of Anaesthetists awarded by the National Institute of Academic Anaesthesia. All funding was unrestricted. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript. This work was conducted at the Southampton NIHR Biomedical Research Centre with subjects studied within the Southampton NIHR Clinical Research Facility. DZL: On the board of CPX International a society supporting cardiopulmonary exercise testing and a member of the fit-4-surgery research group in Southampton. DL has received unrestricted research support from Pharmacosmos Ltd. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript. This work was conducted at the Southampton NIHR Biomedical Research Centre with subjects studied within the Southampton NIHR Clinical Research Facility."

"Funding The study was funded by Pharmacosmos A/S, Holbaek, Denmark, and all funding was unrestricted. Pharmacosmos played no role in study design, data collection or analysis. They retain the right to review any publication prior to publication, but the sponsor has final editorial control (University Hospital Southampton NHS Foundation Trust). JOMP, JMO, DZL and MPWG work within the University of Southampton NIHR Biomedical Research Centre, which received a portion of funding from the UK Department of Health Research Biomedical Research Centres funding scheme. All funding was unrestricted. HEM is supported by University College London Hospitals’ National Institute of Health Research Biomedical Research Centre (NIHR BRC at UCLH), to whom we express our thanks."

"Trial registration ClinicalTrials.gov identifier: NCT 033 46213. "